50% Off Your Order*

Easter Savings!!

Take 50% Off!
Buy 2 Get 1 Free

Blend CJC 1295 NO DAC 5MG with Ipamorelin 5MG

Availability: In stock

$0.00
  • Free Priority Shipping
  • With Purchase over $99 | USA ONLY

Buy 2 Get 1 Free Blend CJC 1295 NO DAC 5MG with Ipamorelin 5MG :

Unit Size 10 mg/ vial
Unit Quantity 1 vial
Purity (Mass Spectrometry and UV) 100%
Appearance Lyophilized White Powder
Source Chemical Synthesis
Storage
Lyophilized Blend CJC 1295 NO DAC with Ipamorelin is Stable
at roomTemperature for 90 days, however it is best to store in a freezer
below - 8c for any extended period of time. After reconstitution
Blend CJC 1295 NO DAC with Ipamorelin should be
refrigerated at temperatures not to exceed 35 F.
Terms The products we offer are intended for laboratory
research use only. Please familiarize yourself with
our terms of service prior to ordering.

 

Blend CJC 1295 NO DAC 5MG with Ipamorelin 5MG is a combination of two synthetic peptides that are analogs of human growth hormone-releasing hormone (GHRH). Both peptides contain an amino acid sequence (the first 29 of 44 amino acids) of GHRH and retain all of its biological properties. The combination functions exactly like GHRH and can be used for a variety of in vitro experiments studying growth and development. (1,2)

Both peptides have been tested in animals and have shown an increase in GH release when compared to control groups.(2,3) Furthermore, the CJC-1295 peptide has been found to increase the release of insulin-like growth factor 1 (IGF-1) in animals. (4) Ipamorelin, on the other hand, was found to be linked with normal bone formation and structure. Over the course of 8 weeks, the researchers examined the effects of ipamorelin, growth hormone, and other growth hormone-releasing peptides on bone development in rats. The findings revealed that ipamorelin was associated with a significant increase in bone mineral content (tested by post-mortem bone scans).(5)

According to studies, synthetic CJC-1295 peptide has superior pharmacokinetic and pharmacodynamic properties to intrinsic GHRH. Especially in the case of CJC-1295 NO-DAC, modification of the original amino acid sequence from the backbone structure of GHRH inhibits peptidase metabolism, improving the stability of the peptide in cell culture experiments. (6)

The combination of peptides has effects on several systems, including GH release, obesity, insulin, immunity, cell differentiation, and metabolism, making it a useful tool to study growth and metabolic disorders in an in vitro setting.

It should be noted that both peptides are synthesized in the laboratory, combined, and distributed commercially for research purposes only. Ingesting the product or using it for any other purpose can be harmful to humans.

The combination of peptides comes as a white lyophilized powder in a concentration of 10 mg/vial (5 mg of each peptide).

References: 1. Matsoukas MT, Spyroulias GA. Dynamic properties of the growth hormone releasing hormone receptor (GHRHR) and molecular determinants of GHRH binding. Mol Biosyst. 2017;13(7):1313-1322. 2. Raun K, Hansen BS, Johansen NL, Thøgersen H, Madsen K, Ankersen M, Andersen PH. Ipamorelin, the first selective growth hormone secretagogue. Eur J Endocrinol. 1998 Nov;139(5):552-61. 3. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8. 4. Campbell RM, Stricker P, Miller R, Bongers J, Liu W, Lambros T, Ahmad M, Felix AM, Heimer EP. Peptides. Enhanced stability and potency of novel growth hormone-releasing factor (GRF) analogues derived from rodent and human GRF sequences. 1994;15(3):489-95. 5. Svensson J, Lall S, Dickson SL, Bengtsson BA, Rømer J, Ahnfelt-Rønne I, Ohlsson C, Jansson JO. The GH secretagogues ipamorelin and GH-releasing peptide-6 increase bone mineral content in adult female rats. J Endocrinol. 2000 Jun;165(3):569-77. 6. Jetté L, Léger R, Thibaudeau K, Benquet C, Robitaille M, Pellerin I, Paradis V, van Wyk P, Pham K, Bridon DP. Human growth hormone-releasing factor (hGRF)1-29-albumin bioconjugates activate the GRF receptor on the anterior pituitary in rats: identification of CJC-1295 as a long-lasting GRF analog. Endocrinology. 2005;146(7):3052-8.